AI tool aims to tailor diuretic doses for heart failure patients
NCT ID NCT07470554
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study analyzes data from over 4,200 heart failure patients to create a tool that uses biomarkers to guide diuretic dosing. Researchers aim to develop a machine-learning algorithm that could personalize treatment and improve outcomes. The study is observational and does not test a new drug or intervention.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a machine-learning algorithm that helps doctors choose the right diuretic dose for each heart failure patient, potentially reducing hospitalizations and deaths.
What could go wrong
This is a retrospective study using existing data, not a new treatment trial. The algorithm needs to be tested in future prospective studies before it can be used in practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Heart Failure and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Emilia-Romagna, 40138, Italy